Ultragenyx Pharmaceutical Inc.
RARENext catalyst
setrusumab
Osteogenesis Imperfecta, Type I
Get an email about RARE's next catalysts
Track Ultragenyx Pharmaceutical (RARE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 3 readout).See the timeline
2 upcoming, 1 past
setrusumab Phase 3 Est. Readout
Estimated primary completion for setrusumab trial (NCT06636071) in Osteogenesis Imperfecta. Topline data typically follows completion by weeks to months.
SourceTriheptanoin Phase 3 Est. Readout
Primary completion for Triheptanoin trial (NCT05933200) in Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
SourceHow RARE's past catalysts played out
Market Overview
Stock performance and key metrics
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Websiteaceneuramic acid extended-release (Ace-ER)
Hereditary Inclusion Body Myopathy
UX111
MPS IIIA
UX003
MPS 7
Oral Corticosteroids
OTC Deficiency
Bisphosphonate
Osteogenesis Imperfecta
GTX-102
Angelman Syndrome
Triheptanoin
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Oral prednisolone
Glycogen Storage Disease Type IA
setrusumab
Osteogenesis Imperfecta, Type I
Burosumab
Hypophosphatemia
Evinacumab
Homozygous Familial Hypercholesterolemia
Adjuvant IM Therapy
MPS IIIA
Prophylactic Immunomodulatory (IM) Therapy
MPS IIIA
Sodium Acetate
OTC Deficiency
Optimized Prophylactic IM Therapy
MPS IIIA
Prophylactic Corticosteroid Taper Regimen
Ornithine Transcarbamylase (OTC) Deficiency
SA-IR
GNE Myopathy
Sialic Acid Extended Release (SA-ER)
GNE Myopathy
SA-ER
GNE Myopathy
[6,6-2H2]glucose
Glycogen Storage Disease Type IA
BPS804
Hypophosphatasia
steroid regimen
GSD1
POST Triheptanoin
Frontal Lobe Hypometabolism
Reactive Corticosteroid Taper Regimen
Ornithine Transcarbamylase (OTC) Deficiency
Triheptanoin oil
Huntington Disease
GLUT1 DS
Glut1 Deficiency Syndrome
Standard of Care (SOC)
Wilson Disease
UX007
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
zoledronic acid (optional)
Osteogenesis Imperfecta, Type I
UX016
GNE Myopathy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
aceneuramic acid extended-release (Ace-ER) | Phase 3 | Hereditary Inclusion Body Myopathy | - | - |
UX111 | Phase 3 | MPS IIIA | - | - |
UX003 | Phase 3 | MPS 7 | - | - |
Oral Corticosteroids | Phase 3 | OTC Deficiency | - | - |
Bisphosphonate | Phase 3 | Osteogenesis Imperfecta | - | - |
GTX-102 | Phase 3 | Angelman Syndrome | - | - |
Triheptanoin | Phase 3 | Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) | - | - |
Oral prednisolone | Phase 3 | Glycogen Storage Disease Type IA | - | - |
setrusumab | Phase 3 | Osteogenesis Imperfecta, Type I | - | - |
Burosumab | Phase 3 | Hypophosphatemia | - | - |
Evinacumab | Phase 3 | Homozygous Familial Hypercholesterolemia | - | - |
Adjuvant IM Therapy | Phase 3 | MPS IIIA | - | - |
Prophylactic Immunomodulatory (IM) Therapy | Phase 3 | MPS IIIA | - | - |
Sodium Acetate | Phase 3 | OTC Deficiency | - | - |
Optimized Prophylactic IM Therapy | Phase 3 | MPS IIIA | - | - |
Prophylactic Corticosteroid Taper Regimen | Phase 2 | Ornithine Transcarbamylase (OTC) Deficiency | - | - |
SA-IR | Phase 2 | GNE Myopathy | - | - |
Sialic Acid Extended Release (SA-ER) | Phase 2 | GNE Myopathy | - | - |
SA-ER | Phase 2 | GNE Myopathy | - | - |
[6,6-2H2]glucose | Phase 2 | Glycogen Storage Disease Type IA | - | - |
BPS804 | Phase 2 | Hypophosphatasia | - | - |
steroid regimen | Phase 2 | GSD1 | - | - |
POST Triheptanoin | Phase 2 | Frontal Lobe Hypometabolism | - | - |
Reactive Corticosteroid Taper Regimen | Phase 2 | Ornithine Transcarbamylase (OTC) Deficiency | - | - |
Triheptanoin oil | Phase 2 | Huntington Disease | - | - |
GLUT1 DS | Phase 2 | Glut1 Deficiency Syndrome | - | - |
Standard of Care (SOC) | Phase 2 | Wilson Disease | - | - |
UX007 | Phase 2 | Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) | - | - |
zoledronic acid (optional) | Phase 2 | Osteogenesis Imperfecta, Type I | - | - |
UX016 | Phase 2 | GNE Myopathy | - | - |
GNE Myopathy
3 drugs in this indication
Angelman Syndrome
3 drugs in this indication
Sanfilippo syndrome
3 drugs in this indication
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
2 drugs in this indication
Glycogen Storage Disease Type Ia
2 drugs in this indication
Sanfilippo Syndrome Type A (MPS IIIA)
2 drugs in this indication
MPS IIIA
1 drug in this indication
Hypophosphatasia
1 drug in this indication
GSD1
1 drug in this indication
Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
1 drug in this indication
OTC Deficiency
1 drug in this indication
Hereditary Inclusion Body Myopathy
1 drug in this indication
MPS 7
1 drug in this indication
Ornithine Transcarbamylase (OTC) Deficiency
1 drug in this indication
Wilson Disease
1 drug in this indication
Osteopenia
1 drug in this indication
Osteogenesis Imperfecta, Type I
1 drug in this indication
Osteogenesis Imperfecta
1 drug in this indication
glycogen storage disorder
1 drug in this indication
Sanfilippo syndrome type A
1 drug in this indication
rare neurodegenerative disorder
1 drug in this indication
Treatment of neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome type A) in pediatric patients with preserved neurodevelopmental function
1 drug in this indication
Long-chain fatty acid oxidation disorders (rare inherited metabolic disorders) in adults and children
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Ultragenyx Pharmaceutical Inc.'s drug pipeline?β
CatalystAlert tracks 30 drug candidates in Ultragenyx Pharmaceutical Inc.'s (RARE) pipeline across Phase 3, Phase 2. Its lead program is setrusumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ultragenyx Pharmaceutical Inc.'s next FDA catalyst?β
Ultragenyx Pharmaceutical Inc.'s (RARE) next tracked catalyst is a Phase 3 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RARE biotech catalysts?β
Add RARE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ultragenyx Pharmaceutical Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
